International Assets Investment Management LLC Takes $190,000 Position in Integra LifeSciences Holdings Co. (NASDAQ:IART)

International Assets Investment Management LLC bought a new stake in Integra LifeSciences Holdings Co. (NASDAQ:IART) in the fourth quarter, HoldingsChannel.com reports. The institutional investor bought 4,355 shares of the life sciences company’s stock, valued at approximately $190,000.

A number of other hedge funds and other institutional investors also recently made changes to their positions in IART. Gladius Capital Management LP acquired a new stake in shares of Integra LifeSciences in the third quarter valued at $47,000. Covestor Ltd increased its position in Integra LifeSciences by 82.5% in the third quarter. Covestor Ltd now owns 2,037 shares of the life sciences company’s stock worth $78,000 after purchasing an additional 921 shares during the period. Empirical Asset Management LLC acquired a new stake in Integra LifeSciences in the fourth quarter worth about $212,000. Panagora Asset Management Inc. acquired a new stake in Integra LifeSciences in the third quarter worth about $223,000. Finally, Great Lakes Advisors LLC acquired a new stake in Integra LifeSciences in the third quarter worth about $229,000. 84.78% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of analysts recently commented on IART shares. Citigroup upgraded Integra LifeSciences from a “sell” rating to a “neutral” rating and set a $38.00 price objective for the company in a research report on Wednesday, April 3rd. JMP Securities cut their price objective on Integra LifeSciences from $55.00 to $49.00 and set a “market outperform” rating on the stock in a report on Thursday, February 29th. Truist Financial cut their price objective on Integra LifeSciences from $46.00 to $41.00 and set a “hold” rating on the stock in a report on Friday, March 1st. Finally, StockNews.com cut Integra LifeSciences from a “buy” rating to a “hold” rating in a report on Friday, April 5th. Two analysts have rated the stock with a sell rating, four have given a hold rating and four have given a buy rating to the company. According to data from MarketBeat, Integra LifeSciences presently has an average rating of “Hold” and a consensus price target of $44.89.

Integra LifeSciences Stock Performance

Shares of NASDAQ IART opened at $28.34 on Monday. The company has a debt-to-equity ratio of 0.94, a current ratio of 3.45 and a quick ratio of 2.18. The stock’s fifty day moving average price is $35.34 and its two-hundred day moving average price is $38.77. Integra LifeSciences Holdings Co. has a one year low of $27.18 and a one year high of $56.21. The firm has a market cap of $2.23 billion, a price-to-earnings ratio of 34.14, a P/E/G ratio of 0.85 and a beta of 1.12.

Integra LifeSciences (NASDAQ:IART) last released its earnings results on Wednesday, February 28th. The life sciences company reported $0.89 earnings per share for the quarter, missing analysts’ consensus estimates of $0.90 by ($0.01). The company had revenue of $397.00 million for the quarter, compared to the consensus estimate of $399.30 million. Integra LifeSciences had a net margin of 4.39% and a return on equity of 15.19%. The business’s revenue was down .3% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.94 earnings per share. On average, equities analysts forecast that Integra LifeSciences Holdings Co. will post 3.19 EPS for the current year.

About Integra LifeSciences

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.